GlassScriptPhysician profile
Lance P Criblez
NPI 1174519342
$14,948.57
in general payments reported to CMS, 2019-2025
55 companies · $2,663 in 2025
The $2,663 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,693 · 2020: $1,416 · 2021: $2,156 · 2022: $1,990 · 2023: $2,180 · 2024: $2,851 · 2025: $2,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,594 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,594.15 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,125.89 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,941.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,716.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,109.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $958.37 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $598.04 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $485.37 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $483.45 | 2019-2025 | Prolia, Evenity, Otezla |
| Otsuka America Pharmaceutical, INC. | $471.79 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.63 | 2019-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $334.29 | 2022-2025 | Auvelity, Sunosi, Symbravo |
| Novartis Pharmaceuticals Corporation | $287.49 | 2019-2025 | |
| Allergan, INC. | $252.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $243.89 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.59 | 2022-2025 | Caplyta |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $212.64 | 2024-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $209.91 | 2019-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $196.86 | 2021 | |
| Abbott Laboratories | $190.29 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $188.56 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $183.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $179.73 | 2019-2023 | Myrbetriq |
| Amarin Pharma, INC. | $173.56 | 2019-2021 | |
| Radius Health, INC. | $154.72 | 2023-2025 | Tymlos |
| Phathom Pharmaceuticals, INC. | $129.39 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $117.82 | 2022 | |
| Sumitomo Pharma America, INC. | $107.95 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $107.26 | 2020-2023 | Livalo, Seglentis |
| Eisai INC. | $98.18 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $91.30 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.58 | 2021-2025 | |
| Esperion Therapeutics, INC. | $82.47 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $80.96 | 2019-2021 | |
| Dexcom, INC. | $65.35 | 2021-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $61.72 | 2025 | Watchman Access System |
| Shield Therapeutics INC | $52.11 | 2023-2024 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $50.73 | 2019-2023 | Eliquis |
| Harmony Biosciences LLC | $48.39 | 2023-2024 | Wakix |
| Edwards Lifesciences Corporation | $47.07 | 2022 | |
| Nestle Healthcare Nutrition INC. | $46.43 | 2021 | |
| Sunovion Pharmaceuticals INC. | $45.61 | 2019-2020 | |
| Kaleo, INC. | $38.00 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $37.61 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $36.53 | 2019-2020 | |
| Viatris Specialty LLC | $29.62 | 2025 | Yupelri |
| Biogen, INC. | $29.29 | 2021-2022 | |
| Lundbeck LLC | $26.98 | 2024 | Rexulti |
| Teleflex LLC | $23.11 | 2024 | Urolift |
| Xeris Pharmaceuticals, INC. | $20.83 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $17.89 | 2023 | |
| Bioventus LLC | $15.33 | 2022 | |
| Circassia INC. | $15.29 | 2019 | |
| Aimmune Therapeutics, INC. | $14.75 | 2024 | |
| Currax Pharmaceuticals LLC | $13.03 | 2021 | |
| Lucid Diagnostics INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Criblez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.